OSL oncosil medical ltd

Strategic Relevance of OncoSil’s Presentation at DDW20251....

  1. 6,553 Posts.
    lightbulb Created with Sketch. 252
    https://hotcopper.com.au/data/attachments/6984/6984967-4c6e8e5f906279ac1e27a6b00e738037.jpg

    Strategic Relevance of OncoSil’s Presentation at DDW2025

    1. Scientific Credibility and Global Platform
    OncoSil’s clinical data was presented at Digestive Disease Week 2025 (DDW2025) in San Diego – one of the world’s largest and most respected conferences focused on gastroenterology, oncology, and gastrointestinal surgery. Hosted by four major US medical societies, DDW draws over 12,000 specialists from more than 70 countries, including:

    • Gastroenterologists and GI surgeons

    • Radiation and medical oncologists

    • Academic researchers and hospital clinical leads

    • Industry stakeholders and health system representatives

    This presentation marks a significant validation of OncoSil’s clinical outcomes in a forum attended by global opinion leaders and frontline practitioners.

    2. Visibility to the FDA
    While the FDA does not exhibit at DDW, its representatives — particularly from the Oncology, Devices, and Drug Evaluation divisions — often attend scientific sessions to track innovation and engage informally with industry and clinicians. OncoSil’s presence at DDW therefore offers valuable indirect visibility to FDA stakeholders, which can support its ongoing regulatory positioning, including breakthrough designation and further US submissions.

    3. Engagement with Pharmaceutical Industry
    Major US and multinational pharmaceutical companies are active attendees at DDW, including Pfizer, Merck, Bristol-Myers Squibb, J&J (Janssen), Roche, Amgen, AstraZeneca, AbbVie, and others. These companies participate to:

    • Identify novel therapeutic devices and adjunctive technologies

    • Monitor competitor pipelines

    • Evaluate licensing or co-development opportunities

    • Engage with clinical trial leaders and data

    OncoSil’s positive survival and surgical conversion data — especially in comparison to SBRT — is well aligned with what pharma companies seek in next-generation oncology partnerships, particularly in the context of combination therapies for pancreatic and other GI cancers.

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$1.14
Change
-0.015(1.30%)
Mkt cap ! $21.46M
Open High Low Value Volume
$1.16 $1.16 $1.14 $32.51K 28.26K

Buyers (Bids)

No. Vol. Price($)
3 14293 $1.14
 

Sellers (Offers)

Price($) Vol. No.
$1.15 8971 2
View Market Depth
Last trade - 15.59pm 28/07/2025 (20 minute delay) ?
OSL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.